Sarah Paul

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

David R. Gandara, Sarah Paul, Marcin Kowanetz et al. · Nature Medicine · 2018 · 1.2K citations

Oncology, Pathology, Bronchial Neoplasm +5

Cold-Inducible Zfp516 Activates UCP1 Transcription to Promote Browning of White Fat and Development of Brown Fat

Jon Dempersmier, Audrey Sambeat, Sarah Paul et al. · Molecular Cell · 2015 · 249 citations · Full text

Transcriptional Regulation, Signal Transduction, Signaling Pathway +13

LSD1 Interacts with Zfp516 to Promote UCP1 Transcription and Brown Fat Program

Audrey Sambeat, Jon Dempersmier, Kevin M. Tharp et al. · Cell Reports · 2016 · 99 citations · Full text

Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK)

David R. Gandara, Marcin Kowanetz, Tony Mok et al. · Annals of Oncology · 2017 · 84 citations · Full text

Tumor Mutational Burden, Oncology, Medicine +9

Association of high tissue TMB and atezolizumab efficacy across multiple tumor types.

Fatema A. Legrand, David R. Gandara, Sanjeev Mariathasan et al. · Journal of Clinical Oncology · 2018 · 57 citations

Immunology, Pathology, Oncology +16